MYC-mediated synthetic lethality for treatment of hematological malignancies

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Deregulated c-MYC expression drives numerous human cancers, making MYC a key therapeutic target.
• MYC inactivation can induce tumor regression, but clinical applications for targeted inactivation remain limited.
• MYC-driven cancers can exhibit dual oncogene addiction, presenting opportunities for synthetic lethality strategies.

Purpose of the Study:

• To explore the concept of MYC-mediated synthetic lethality (MYC-SL) for cancer treatment.
• To investigate the efficacy of small molecule inhibitors (SMIs) in inducing MYC-SL.
• To evaluate the potential of combining SMI-induced MYC-SL with conventional chemotherapy.

Main Methods:

• Review of studies establishing MYC-SL and identifying targetable pathways.
• Analysis of small molecule inhibitors (SMIs) that induce MYC-SL by targeting key proteins and pathways.
• Evaluation of SMI-induced MYC-SL in reversing chemoresistance and enhancing chemotherapy efficacy.

Main Results:

• MYC overexpression sensitizes cancer cells to apoptosis-inducing agents, forming the basis for MYC-SL.
• Numerous SMIs targeting pathways like AUK-B, Brd4, and mTOR have demonstrated MYC-SL.
• SMI-induced MYC-SL exhibits high selectivity against cancer cells with low toxicity to normal cells.
• Combination therapy with SMIs and chemotherapy enhances treatment efficacy and overcomes chemoresistance.

Conclusions:

• MYC-mediated synthetic lethality represents a promising strategy for treating MYC-dependent tumors.
• Small molecule inhibitors offer a targeted approach to induce MYC-SL with improved safety profiles.
• Combining SMIs with chemotherapy could revolutionize treatment for various MYC-driven malignancies.